Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedPointe Pumps Up The Volume On Astelin Marketing Campaign

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm’s new marketing program for the nasal spray includes a direct-to-consumer advertising campaign and an increase in sales reps.

You may also be interested in...



Inspire Reports Positive Phase II Results For Allergic Rhinitis Spray

Firm tells “The Pink Sheet” DAILY it hopes to differentiate epinastine by focusing on its non-steroidal characteristic and less bitter taste.

Inspire Reports Positive Phase II Results For Allergic Rhinitis Spray

Firm tells “The Pink Sheet” DAILY it hopes to differentiate epinastine by focusing on its non-steroidal characteristic and less bitter taste.

Sepracor, MedPointe To End Astelin Co-Promotion Agreement

The companies will continue to detail the product until June 30, then Sepracor will be responsible for sample coverage until the end of the year. Sepracor plans to focus sales efforts on in-house products.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel